Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ochre Bio logo —

Ochre Bio

Founded 2019 United Kingdom Oxford, United Kingdom 59 employees Series A Total: $39.88M Biotechnology, Pharmaceutical

General Information

Company Name Ochre Bio
Founded Year 2019
Location United Kingdom Oxford, United Kingdom
Employees 59
Industries Biotechnology, Pharmaceutical
Funding Stage Series A
Business Model B2B, B2B2B, API
Revenue Model Licensing, Performance Based, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with Ochre Bio. To contact Ochre Bio, visit ochre-bio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ochre Bio compare?

A PDF of Ochre Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ochre Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 04, 2026

Ochre Bio leadership will attend The Liver Meeting 2026 in Denver.

Board Appointment Oct 08, 2026

Ochre Bio formed its Clinical Translation Board, led by Eduardo Bruno Martins.

Ochre Bio a competitor of yours? Have our desk watch it

About Ochre Bio

Ochre Bio is a dynamic biotechnology company founded in 2019 in the United Kingdom. Specializing in the development of RNA therapies for chronic liver diseases, the company leverages genomic deep phenotyping and precision RNA medicine.

Ochre Bio's innovative approach involves testing therapies in live human donor livers, highlighting their commitment to advancing liver health solutions. By focusing on increasing donor liver supply and reducing cirrhosis complications, they address pressing healthcare challenges in the biotechnology and pharmaceutical industries.

Recently, the company secured a Series A investment on 01 October 2023, with contributions from investors such as Gaingels and STCAP. This funding will likely bolster Ochre Bio's research efforts and facilitate the continued development of groundbreaking RNA therapies for liver disease.

Business keywords: RNA Therapies, Chronic Liver Diseases, Genomic Deep Phenotyping, Precision Medicine, Transplant Enhancement, Liver Rejuvenation, Genomics, Liver Health, Cirrhosis Complications, Advanced Therapies, Liver Genomics Research, Biotech Innovation

Services & Products

Development of RNA therapies
AI-driven drug discovery
Human liver data integration
Validation in human liver models

Target Customers

Pharmaceutical companies Biotech researchers Medical institutions focusing on liver diseases Investors in advanced biotech innovations

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 2
Gaingels STCAP
Gaingels, STCAP
01 Oct 2023
Series A $30.00M 11
BACKED Khosla Ventures AixThera
BACKED, Khosla Ventures +9
01 Oct 2022
Series A Undisclosed 2
Acequia Capital FAST — by GETTYLAB
Acequia Capital, FAST — by GETTYLAB
01 Dec 2021
Seed $9.60M 6
BACKED Apollo Health Ventures Hoxton Ventures
BACKED, Apollo Health Ventures +4
01 Jun 2021
Seed $130.00K 1
Y Combinator
Y Combinator
01 Aug 2020
Support Program $150.00K 2
Y Combinator Khosla Ventures
Y Combinator, Khosla Ventures
01 Mar 2020

Ochre Bio Alternatives & Competitors

View All Alternatives
Ochre Bio vs
Yaqrit
Yaqrit United Kingdom

The Liver Disease Company

Convertible Note
14 employees
Biotechnology, Health Care
Compare Ochre Bio vs Yaqrit
Ochre Bio vs
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. United States

At Avidity, we are developing a new class of oligonucleotide-based therapies.

IPO
447 employees
Biotechnology, Health Care
Compare Ochre Bio vs Avidity Biosciences, Inc.
Ochre Bio vs
Kernal Biologics
Kernal Biologics United States

KernalBio creates mRNA therapies that instruct specific cells on how to make their own medicine

Series A
22 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Ochre Bio

Ochre Bio was founded in 2019.
Ochre Bio is headquartered in Oxford, United Kingdom.
Ochre Bio operates in Biotechnology and Pharmaceutical. Its work centres on RNA Therapies, Chronic Liver Diseases, Genomic Deep Phenotyping and Precision Medicine. Its customers include Pharmaceutical companies, Biotech researchers and Medical institutions focusing on liver diseases.
Ochre Bio has a B2B, B2B2B and API business model. Its revenue comes from Licensing, Performance Based and Data Monetization.
Ochre Bio has approximately 59 employees.
Ochre Bio has completed 6 funding rounds, raising a total of $39.88M. The latest funding stage is Series A.
Ochre Bio offers: Development of RNA therapies, AI-driven drug discovery, Human liver data integration, Validation in human liver models.
Top alternatives and competitors to Ochre Bio include Yaqrit, Avidity Biosciences, Inc., Kernal Biologics, Lifebit, GLG Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ochre Bio and Yaqrit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ochre Bio, https://bouncewatch.com/company/ochre-bio, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout